Laurus Labs CDMO Revenue Surges 67% on Small Molecule API Demand
- Laurus Labs' CDMO business grew 67% year-over-year to ₹870 crore ($99.4M) in Q1 FY2027, driven by small molecule APIs rising 69% to ₹835 crore ($95.4M).
- The company secured land in Visakhapatnam for a new manufacturing facility and in-licensed two antibody-drug conjugates, signaling capacity expansion and portfolio diversification.
- Consolidated net profit more than doubled to ₹361.99 crore ($41.4M) with EBITDA margin improving to 31.8% due to higher capacity utilization.
Operational Impact
Laurus Labs' accelerating small molecule CDMO capacity and new Visakhapatnam facility acquisition expand late-stage clinical and commercial API supply options for sponsors seeking alternatives to congested contract manufacturers.
Source: PharmaSource RSS
AsymBio Breaks Ground on Shanghai Fengxian R&D Building for Biologics Development
- AsymBio is constructing an eight-story, 20,000-square-meter R&D building at its Shanghai Fengxian site, with completion targeted for H2 2027.
- The facility will support cell line development, upstream/downstream process development, ADC conjugation, drug product development, and analytical services, positioned adjacent to clinical and commercial manufacturing lines.
- The building will house AccPCC, an AI-enabled platform designed to accelerate development timelines from lead compound to preclinical candidate selection and integrate early R&D with CMC and manufacturing scale-up.
Operational Impact
AsymBio's Fengxian R&D expansion adds integrated biologics development capacity in APAC, enabling tighter CMC-to-manufacturing alignment and potentially reducing project timelines for sponsors developing antibodies and ADCs in the region.
Source: Contract Pharma Breaking News RSS
Asymchem's Jilin Carbapenem API Facility Clears First FDA Pre-Approval Inspection
- Asymchem's DH2 carbapenem API facility in Jilin, China passed its first USFDA Pre-Approval Inspection in April–June 2026, supporting commercial continuous-flow manufacturing.
- The facility, commissioned in 2020, features in-house continuous ozonolysis technology at tonnage scale and supplies custom carbapenem intermediates for clinical and commercial programs.
- Asymchem operates 200+ annual customer audits and has completed over 100 regulatory inspections globally, applying Quality by Design frameworks across its CDMO network.
Operational Impact
Asymchem's DH2 facility PAI clearance establishes a validated carbapenem API source with continuous-flow capacity, reducing supply-chain risk for CDMO customers developing or commercializing carbapenem-based therapeutics.
Source: PharmaSource RSS
References
- PharmaSource RSS — Laurus Labs CDMO Revenue Surges 67% on Small Molecule API Demand
- Contract Pharma Breaking News RSS — AsymBio Breaks Ground on Shanghai Fengxian R&D Building for Biologics Development
- PharmaSource RSS — Asymchem's Jilin Carbapenem API Facility Clears First FDA Pre-Approval Inspection